This possibility is confirmed by observations that the mammalian target of rapamycin (mTOR), an upstream regulator of HIF, is activated in human gastric cancer, whereas attenuation of PI-3K/Akt/mTOR-mediated signalling by rapamycin effectively blocks HIF-1α in gastric cell lines [355]. The gene discussed is HIF1A; the disease is gastric cancer.